Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MDAI
MDAI logo

MDAI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.880
Open
1.860
VWAP
1.79
Vol
212.10K
Mkt Cap
55.37M
Low
1.735
Amount
378.60K
EV/EBITDA(TTM)
--
Total Shares
31.82M
EV
56.27M
EV/OCF(TTM)
--
P/S(TTM)
3.15
Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.
Show More

Events Timeline

(ET)
2026-05-26
07:10:00
Spectral AI's DeepView System Receives FDA De Novo Classification
select
2026-04-08 (ET)
2026-04-08
08:50:00
Spectral AI Appoints David McGuire as CFO
select
2026-03-24 (ET)
2026-03-24
16:30:00
Spectral AI Q4 Revenue $3.8M Beats Expectations
select
2026-03-24
16:30:00
FY26 Revenue Outlook Reflects Development of DeepView System
select
2026-03-18 (ET)
2026-03-18
16:40:00
Spectral AI Secures $31.7M Funding from BARDA
select
2026-02-10 (ET)
2026-02-10
08:40:00
Spectral AI Appoints Vincent Capone as CEO
select
2025-11-11 (ET)
2025-11-11
16:01:47
Spectral AI Announces Q3 Earnings Per Share of 13 Cents, Exceeding Consensus Estimate of 9 Cents
select
2025-10-23 (ET)
2025-10-23
08:34:14
Spectral AI sets share price at $1.90 for 4 million shares in offering
select

News

Newsfilter
8.5
06-25Newsfilter
Spectral AI Wins First Prize at British Burn Association Conference
  • Award for Innovation: Spectral AI's DeepView System won first prize at the British Burn Association Conference, showcasing its advanced diagnostic capabilities in burn care and further solidifying the company's leadership in medical diagnostics.
  • FDA and UKCA Approvals: The company received De Novo classification from the FDA in May 2026 and UKCA authorization in February 2024, marking compliance and application potential for the DeepView system in global markets, which is expected to drive sales growth.
  • Clinical Application Feedback: Shreyas Supparamaniam from Pinderfields Hospital highlighted the real-world impact of the DeepView system in burn management, emphasizing its ability to provide immediate objective assessments that enable physicians to make more informed treatment decisions, thereby improving patient care quality.
  • Enhanced Industry Influence: Spectral AI's active participation and multiple presentations at the conference underscore its significant role in advancing burn care, which is likely to attract more healthcare institutions to its innovative technology.
Newsfilter
8.5
06-12Newsfilter
Spectral AI Celebrates Wound Healing Awareness Month with AI Innovations
  • AI Technology in Wound Management: Spectral AI's DeepView System received FDA De Novo classification in May 2026, integrating multispectral imaging with AI algorithms to capture images in 0.2 seconds and process them in 20 to 25 seconds, significantly enhancing the efficiency of assessing burn healing potential, thereby enabling clinicians to make faster treatment decisions.
  • Improving Patient Quality of Life: By rapidly and objectively evaluating the healing potential of acute burns, the DeepView System aims to enhance the quality of life for patients and their families, particularly in complex burn cases, by timely identifying areas that may require significant medical intervention to ensure appropriate treatment.
  • Industry Recognition and Mission: Spectral AI was named one of TIME's Top HealthTech Companies of 2025, highlighting its innovative capabilities and industry impact in medical diagnostics, further advancing the professionalization and standardization of wound care.
  • Collaboration with ABWM: In celebration of the 10th Annual Wound Healing Awareness Month, Spectral AI collaborates with the American Board of Wound Management Foundation to emphasize the vital role of wound care specialists in enhancing patient care quality, aiming to promote advancements in wound management through education and research.
Newsfilter
8.5
06-11Newsfilter
Spectral AI to Showcase DeepView System at British Burn Association Annual Meeting
  • Technology Showcase: Spectral AI will display its DeepView® System at the British Burn Association Annual Meeting from June 17-19, 2026, which is expected to attract burn care professionals from the UK and beyond, enhancing the company's visibility in the medical diagnostics field.
  • FDA Approval: The DeepView System received De Novo Classification from the FDA in May 2026, marking its innovative position in burn wound assessment technology, which is anticipated to boost the company's competitiveness and long-term shareholder value.
  • Commercial Sales Expectations: The company expects to achieve its first commercial sales of the DeepView System by the end of 2026, a milestone that will provide new revenue streams and further solidify its position in the medical device market.
  • Clinical Application Potential: The DeepView System combines multispectral imaging with AI algorithms, capturing images in 0.2 seconds and processing them in 20-25 seconds, providing clinicians with rapid, data-driven assessments of wound healing potential, thereby improving patient outcomes and reducing healthcare costs.
NASDAQ.COM
9.0
05-26NASDAQ.COM
Spectral AI Shares Drop 12% After FDA De Novo Classification
  • Stock Decline: Shares of Spectral AI, Inc. fell approximately 12% in Tuesday morning trading, currently priced at $2.34, down 12.72% from the previous close of $2.68, indicating a negative market reaction to the news.
  • FDA Approval: The company announced that its DeepView System received De Novo Classification from the U.S. Food and Drug Administration, allowing it to be used in burn care across various settings, paving the way for future commercial distribution activities.
  • Historical Trading Range: Over the past year, Spectral AI's stock has fluctuated between $1.18 and $3.21, with the current price nearing the year's low, reflecting market concerns about the product's prospects.
  • Commercial Activity Launch: With the De Novo Classification, Spectral AI is authorized to commence commercial distribution activities in the U.S., a significant development that, despite its importance, has not been positively reflected in market reactions.
Newsfilter
8.5
05-26Newsfilter
Spectral AI Receives FDA De Novo Classification for DeepView System
  • FDA Milestone: Spectral AI's DeepView System has received De Novo classification from the FDA, marking a significant advancement in the medical diagnostics field and is expected to accelerate the company's commercial distribution activities in the U.S., thereby enhancing its competitiveness in the trauma care market.
  • Technological Innovation: The DeepView System combines multispectral imaging with a proprietary AI algorithm, enabling image acquisition in 0.2 seconds and processing within 20 to 25 seconds, providing clinicians with rapid, data-driven assessments of wound healing potential, significantly improving treatment decision efficiency.
  • Market Potential: Designed to redefine the standard of care in burn treatment, the system is anticipated to deliver value across the healthcare ecosystem by improving patient outcomes and reducing costs, further solidifying the company's leadership position in the medical technology sector.
  • Strategic Support: The project is partially funded by the U.S. Department of Health and Human Services and the Biomedical Advanced Research and Development Authority (BARDA), highlighting government support for innovative medical technologies, which may provide a strong backing for Spectral AI's future expansion and development.
Globenewswire
3.5
05-13Globenewswire
MindBio Leverages AI Voice Analysis for Impairment Detection
  • Technological Innovation: MindBio Therapeutics is developing a platform that combines AI and voice analysis to detect impairment from multiple substances in real-time, addressing a significant gap in existing detection technologies and potentially enhancing public safety and health response capabilities.
  • Market Potential: The company targets a market of approximately $47 billion in workplace safety and substance testing, aiming to drive industry efficiency and compliance through the application of non-invasive detection technologies to meet growing market demands.
  • Scientific Basis: MindBio's technology is grounded in clinical trial data from over 50 million data points, enabling efficient identification of impairment signatures from various substances, providing a more comprehensive assessment than traditional single-substance tests, which holds significant clinical and societal implications.
  • Industry Impact: By facilitating real-time impairment detection, MindBio's technology could reduce traffic and workplace accidents, enhancing overall societal safety, aligning with the global urgent need for rapid, scalable detection solutions.
Wall Street analysts forecast MDAI stock price to rise
2 Analyst Rating
Wall Street analysts forecast MDAI stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
3.00
Averages
4.50
High
6.00
Current: 0.000
sliders
Low
3.00
Averages
4.50
High
6.00
BTIG
Buy
maintain
$3 -> $4
AI Analysis
2026-05-26
Reason
BTIG
Price Target
$3 -> $4
AI Analysis
2026-05-26
maintain
Buy
Reason
BTIG raised the firm's price target on Spectral AI to $4 from $3 and keeps a Buy rating on the shares after the company announced it received FDA clearance for the DeepView System for Burn Centers, Trauma Centers, and Emergency Departments. FDA clearance is a significant milestone for the company as the DeepView System has been in development and clinical investigation for numerous years, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Spectral AI Inc (MDAI.O) is 52.36, compared to its 5-year average forward P/E of 2.97. For a more detailed relative valuation and DCF analysis to assess Spectral AI Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
2.97
Current PE
52.36
Overvalued PE
16.79
Undervalued PE
-10.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-20.81
Current EV/EBITDA
-5.34
Overvalued EV/EBITDA
2.08
Undervalued EV/EBITDA
-43.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
5.46
Current PS
2.56
Overvalued PS
10.59
Undervalued PS
0.32

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

high volume low float stocks today
Intellectia · 31 candidates
Market Cap: 50.00M - 5.00BRegion: USPrice: $1.00 - $50.00Volume: >= 1,000,000Relative Vol: >= 2Floating Shares: <= 30,000,000
Ticker
Name
Market Cap$
top bottom
BATL logo
BATL
Battalion Oil Corp
95.48M
PAYS logo
PAYS
Paysign Inc
283.70M
FUBO logo
FUBO
FuboTV Inc
1.18B
SLND logo
SLND
Southland Holdings Inc
71.43M
KSCP logo
KSCP
Knightscope Inc
77.31M
AGRO logo
AGRO
Adecoagro SA
2.10B
stocks to buy under 2 $ today
Intellectia · 46 candidates
Market Cap: >= 50.00MPrice: $0.20 - $2.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20
Ticker
Name
Market Cap$
top bottom
PROP logo
PROP
Prairie Operating Co
84.70M
REI logo
REI
Ring Energy Inc
301.53M
MVIS logo
MVIS
MicroVision Inc
215.19M
BLND logo
BLND
Blend Labs Inc
442.24M
HAIN logo
HAIN
Hain Celestial Group Inc
56.02M
UPXI logo
UPXI
Upexi Inc
81.62M

Whales Holding MDAI

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Spectral AI Inc (MDAI) stock price today?

The current price of MDAI is 1.74 USD — it has decreased -6.95

What is Spectral AI Inc (MDAI)'s business?

Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.

What is the price predicton of MDAI Stock?

Wall Street analysts forecast MDAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDAI is4.50 USD with a low forecast of 3.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Spectral AI Inc (MDAI)'s revenue for the last quarter?

Spectral AI Inc revenue for the last quarter amounts to 3.99M USD, decreased -40.50

What is Spectral AI Inc (MDAI)'s earnings per share (EPS) for the last quarter?

Spectral AI Inc. EPS for the last quarter amounts to -0.11 USD, decreased -191.67

How many employees does Spectral AI Inc (MDAI). have?

Spectral AI Inc (MDAI) has 65 emplpoyees as of July 08 2026.

What is Spectral AI Inc (MDAI) market cap?

Today MDAI has the market capitalization of 55.37M USD.